Open AccessDonor‐Matched Stem Cell Transplant Improves Outcomes in Older Patients with High‐Risk MDS
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13644
Subject(s) - medicine , myelodysplastic syndromes , stem cell , clinical trial , hematopoietic stem cell , hematopoietic stem cell transplantation , oncology , hematopoietic cell , transplantation , intensive care medicine , haematopoiesis , bone marrow , genetics , biology
Allogeneic hematopoietic stem cell transplant, once considered too risky for older patients with myelodysplastic syndrome (MDS), is associated with significantly improved survival for those with matched donors relative to non‐transplant treatment. New findings from the Blood and Marrow Transplant Clinical Trials Network suggest a revised standard of care for older patients with MDS.